ArticleBrain and behavior2026
Natural History and Factors Influencing 90-Day Clinical Outcomes and 1-Year Recurrence of Thalamic Stroke.
Article in Brain and behavior, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the natural course of cerebral small vessel disease (CSVD) manifested as pure thalamic infarction (PTI) and identify predictors of 90-day clinical prognosis and 1-year recurrent major adverse cardiovascular/cerebrovascular events (MACE).
methodsThis retrospective cohort study analyzed 251 consecutive thalamic infarction patients admitted between January 2016 and May 2024. Participants were classified into PTI (n = 187) or combined-type thalamic infarction (CTI, n = 64). Primary endpoints included poor 90-day clinical prognosis (modified Rankin Scale [mRS] ≥ 2) and 1-year MACE (composite of stroke, acute myocardial infarction, and cardiovascular death). Intergroup comparisons utilized Pearson Chi-square or Mann-Whitney U tests, with variables showing p ≤ 0.10 in univariate analysis entered into multivariate logistic regression models.
resultsCompared with CTI, PTI patients demonstrated lower baseline National Institutes of Health Stroke Scale (NIHSS) scores (median 1 vs. 3, p < 0.001) and reduced prevalence of atrial fibrillation (2.7% vs. 12.5%), intracranial artery stenosis (ICAS; 48.1% vs. 76.6%), and early neurological deterioration (24.6% vs. 56.3%; all p < 0.05). The 90-day poor prognosis rate was significantly lower in PTI (4.8% vs. 20.3%, p < 0.001), whereas 1-year MACE rates did not differ between groups (12.3% vs. 15.6%, p = 0.497). Among PTI cases, territorial distributions comprised inferolateral (80.2%), tuberothalamic (13.4%), paramedian (including Percheron artery, 5.9%), and posterior choroidal arteries (0.5%). Tuberothalamic artery infarctions exhibited higher cognitive impairment rates (36.0%) than other subgroups. Multivariate analysis identified baseline NIHSS as an independent predictor of 90-day poor prognosis (OR = 1.634, 95% CI 1.152-2.320, p = 0.006), while ICAS was associated with 1-year MACE (OR = 3.908; 95% CI, 1.188-12.849; p = 0.025) in PTI patients.
conclusionPTI presented favorable short-term outcomes, consistent with initial stroke severity, yet carried a 12.3% annual MACE risk, particularly in patients with coexisting ICAS. These findings underscore the importance of addressing intracranial stenosis in secondary prevention strategies for CSVD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.